14 unknown, 2 completed, 1 active not recruiting, 1 recruiting. 9 Phase 2, 4 Not applicable, 4 Phase 1, 3 Phase 3, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 6, Completed 2, Terminated 1 |
| Not applicable | 4 | Unknown 4 |
| Phase 1 | 4 | Unknown 2, Recruiting 1, Terminated 1 |
| Phase 3 | 3 | Unknown 2, Active not recruiting 1 |
| Early Phase 1 | 2 | Unknown 2 |
Follow CF regimen: new trials by email Literature Review of CF regimen trials Research Report on CF regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MOv19-BBz CAR T Cells in FRa+ Cancers MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing - Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Recruiting | University of Pennsylvania | 10 | 2025-10-07 | 2026-10-07 |
| Chidamide Bridging for CAR-T Therapy Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2022-05-25 | 2024-03-06 |
| Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab） - Esophageal Squamous Cell Carcinomas | Phase 2 | Unknown | Shanghai Chest Hospital | 54 | 2021-12-01 | 2021-11-02 |
| Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide,Fludarabine - CD19+ and CD 22+ B-ALL | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 100 | 2021-08-15 | 2022-02-07 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies CT125A cells, Cyclophosphamide, fludarabine - CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Unknown | Huazhong University of Science and Technology | 18 | 2021-03-01 | 2021-02-23 |
| A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia Cyclophosphamide-Fludarabine (Cy/Flu), oNKord® - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Glycostem Therapeutics BV | 33 | 2020-12-08 | 2022-06-21 |
| A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Non-hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 200 | 2020-10-22 | 2020-12-14 |
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Plasma Cell Tumors | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 60 | 2020-10-22 | 2020-12-11 |
| A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-10-22 | 2020-12-29 |
| Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC Durvalumab, Placebo, cisplatin + fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 640 | 2020-10-19 | 2026-10-13 |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Leukemia, Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 30 | 2020-06-23 | 2020-10-30 |
| Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Wei Jiang | 440 | 2015-03-01 | 2018-05-16 |
| Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer Ultrasound Hyperthermia, Docetaxel,Cisplatin,Fluorouracil - Head and Neck Cancer | Phase 2 | Unknown | Wei Guo | 120 | 2014-12-01 | 2015-02-02 |
| P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. Interferon Alfa、Fluorouracil, Cisplatin、Fluorouracil - Hepatocellular Carcinoma | Phase 2 | Unknown | Kansai Hepatobiliary Oncology Group | 66 | 2013-03-01 | 2018-05-18 |
| Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) neoadjuvant docetaxel/cisplatin/fluorouracil, No treatment before definitive CCRT - Hypopharyngeal Cancer | Phase 2 | Completed | Samsung Medical Center | 40 | 2010-11-01 | 2019-12-09 |
| Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer cisplatin, Fluorouracil - Advanced Gastric Cancer | Phase 2 | Unknown | Fudan University | 79 | 2009-08-01 | 2010-09-08 |
| Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) nimotuzumab, PF regimen (cisplatin and 5-FU) - Head and Neck Cancer | Phase 2 | Completed | Fudan University | 40 | 2009-05-01 | 2012-02-20 |
| Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Cisplatin,fluorouracil, Cisplatin - Nasopharyngeal Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 506 | 2006-06-01 | 2013-07-12 |
| Stem Cell Transplantation for Fanconi Anemia Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation - Fanconi Anemia | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 16 | 2004-03-01 | 2019-08-26 |
Head and Neck Neoplasms (3) · Hematologic Neoplasms (2) · Leukemia (2) · Lymphoma, Non-Hodgkin (2) · Nasopharyngeal Carcinoma (2) · Adenocarcinoma of Lung (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1) · Fanconi Anemia (1) · Hodgkin Disease (1) · Hypopharyngeal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1)
Hebei Senlang Biotechnology Inc., Ltd. (5) · Fudan University (2) · AstraZeneca (1) · Chinese PLA General Hospital (1) · Glycostem Therapeutics BV (1) · Huazhong University of Science and Technology (1) · Kansai Hepatobiliary Oncology Group (1) · Masonic Cancer Center, University of Minnesota (1) · Samsung Medical Center (1) · Shanghai Chest Hospital (1) · Sun Yat-sen University (1) · University of Pennsylvania (1) · Wei Guo (1) · Wei Jiang (1)
China (12) · United States (3) · Belgium (2) · France (2) · Japan (2) · South Korea (2) · Brazil (1) · Canada (1) · Germany (1) · Mexico (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · Switzerland (1)
Baoen Shan, PhD & MD (3) · Lihong Liu, PhD & MD (3) · Andrew Haas, MD, PhD (1) · Hiroaki Nagano, MD, PhD (1) · Jianfeng Zhou, PhD, MD (1) · Jin Li, MD (1) · Jun Ma, M.D. (1) · Lian Jiang, MD (1) · Luhua Wang, MD (1) · Margaret MacMillan, MD (1) · Nabil Saba, MD (1) · Peihua Lu, PhD&MD (1) · Prof. Dr. Arnold Ganser, MD (1) · Wei Guo, PhD (1) · Wei Jiang, Ph.D. (1)
PMID 22154591, PMID 25824692, PMID 28235726, PMID 36275715, PMID 38143760, PMID 38304826, PMID 38329737, PMID 41633358
2019 (1), R01CA260902 (1)